REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6

被引：0
|
作者：
Tuttle, Katherine [1 ,2 ]
Cherney, David [3 ]
Hadjadj, Samy [4 ]
Idorn, Thomas [5 ]
Mosenzon, Ofri [6 ]
Perkovic, Vlado [7 ]
Rasmussen, Soren [5 ]
Wolthers, Benjamin [5 ]
Bain, Stephen C. [8 ]
机构：
[1] Univ Washington, PMRC, Inst Translat Hlth Sci, Spokane, WA USA
[2] Nephrol Div, Spokane, WA USA
[3] Toronto Gen Hosp, Div Nephrol, Dept Med, Toronto, ON, Canada
[4] Univ Nantes, CNRS, CHU Nantes, Inst Thorax,INSERM, Nantes, France
[5] Novo Nordisk, Soborg, Denmark
[6] Hadassah Hebrew Univ Hosp, Diabet Clin Res Ctr, Jerusalem, Israel
[7] Univ New South Wales, Fac Med, Sydney, NSW, Australia
[8] Swansea Univ, Diabet Res Unit Cymru, Sch Med, Swansea, W Glam, Wales
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2020年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
TO002
引用
收藏
页码：183 / 183
页数：1
相关论文
共 50 条
  • [31] Neutrophil-to-lymphocyte ratio predicts cardiovascular events in patients with type 2 diabetes: post hoc analysis of SUSTAIN 6 and PIONEER 6
    Verma, S.
    Husain, M.
    Madsen, C. M.
    Leiter, L. A.
    Rajan, S.
    Vilsboll, T.
    Rasmussen, S.
    Libby, P.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 253 - 254
  • [32] SUSTAIN 6: A POST-HOC ANALYSIS OF THE EFFECT OF SEMAGLUTIDE ON CARDIOVASCULAR OUTCOMES OVER TIME IN SUBJECTS WITH TYPE 2 DIABETES
    Bellary, S.
    Jodar, E.
    Seufert, J.
    Damgaard, L. H.
    Holst, A. Gaarsdal
    Leiter, L.
    ATHEROSCLEROSIS SUPPLEMENTS, 2018, 34 : E6 - E7
  • [33] Effect of once-weekly semaglutide on insulin use in subjects with type 2 diabetes: a post hoc analysis of SUSTAIN 6
    Seufert, J.
    Desouza, C.
    Kirk, A. R.
    Lawson, J.
    Lingvay, I.
    Sondergaard, A. L.
    Bain, S. C.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 251 - 252
  • [34] SUSTAIN 6: a post-hoc analysis of the effect of semaglutide on cardiovascular outcomes over time in subjects with type 2 diabetes
    Jodar, E.
    Seufert, J.
    Damgaard, L. H.
    Holst, A. G.
    Leiter, L. A.
    EUROPEAN HEART JOURNAL, 2017, 38 : 819 - 819
  • [35] Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
    Husain, Mansoor
    Bain, Stephen C.
    Holst, Anders Gaarsdal
    Mark, Thomas
    Rasmussen, Soren
    Lingvay, Ildiko
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
  • [36] Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials
    Mansoor Husain
    Stephen C. Bain
    Anders Gaarsdal Holst
    Thomas Mark
    Søren Rasmussen
    Ildiko Lingvay
    Cardiovascular Diabetology, 19
  • [37] Semaglutide reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 and PIONEER 6 trials
    Verma, Subodh
    David, Jens-Peter
    Leiter, Lawrence A.
    Michelsen, Marie Mide
    Rasmussen, Soren
    Bhatt, Deepak L.
    DIABETES OBESITY & METABOLISM, 2023, 25 (08): : 2388 - 2392
  • [38] Estimating CVD-free life-years with the addition of semaglutide in people with type 2 diabetes using pooled data from SUSTAIN 6 and PIONEER 6
    Westerink, J.
    Matthiessen, K. Sommer
    Nuhoho, S.
    Fainberg, U.
    Wolden, M. Lyng
    Visseren, F.
    Sattar, N.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S51 - S52
  • [39] EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) - A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER
    Perkovic, Vlado
    Bain, Stephen
    Bakris, George
    Buse, John
    Idorn, Thomas
    Mahaffey, Kenneth
    Marso, Steven
    Nauck, Michael
    Pratley, Richard
    Rasmussen, Soren
    Rossing, Peter
    Tornoe, Karen
    Zinman, Bernard
    Mann, Johannes
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2019, 34 : 205 - U715
  • [40] Reduced glycaemic variability with once-weekly semaglutide vs active comparators in post hoc analysis of the SUSTAIN programme
    Jodar, E.
    Aroda, V. R.
    Kose, Y.
    Kaltoft, M.
    Sondergaard, A. L.
    Pratley, R.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 250 - 250
12345